Home » Archemix Begins Phase IIa Trial for ARC1779
Archemix Begins Phase IIa Trial for ARC1779
Archemix has started a Phase IIa trial to evaluate the safety and efficacy of ARC1779 as an antithrombotic in patients suffering from acute coronary syndrome undergoing percutaneous coronary intervention.
The multinational, dose-ranging, randomized, double-blind trial will enroll approximately 300 patients and use ReoPro as a comparator.
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May